| ABPs | Albumin binding proteins. |
| AD | Alzheimer’s disease. |
| Ag2S | Silver sulfide. |
| AML | Acute myeloid leukemia. |
| AT1 | Angiotensin II type 1. |
| AzMMMan | Azidomethyl-methylmaleic anhydride. |
| Aβ | Amyloid-beta. |
| Bcl-2 | B-cell lymphoma-2. |
| CAT | Catalase. |
| Ce6 | Chlorine e6. |
| CIA | Collagen-induced arthritis. |
| CDs | Carbon dots. |
| CDT | Chemodynamic therapy. |
| CESAR | Copper peroxide-based tumor pH-responsive autocatalytic nanoreactor. |
| CU | Curcumin. |
| CuS | Copper sulfide. |
| Cy5.5 | Cyanine 5.5. |
| cys34 | Cysteine 34. |
| DBCO | Dibenzocyclooctyne. |
| DBCO-Ce6 | DBCO coupled Ce6. |
| DC | Dibenzocyclooctyne/chlorin. |
| DOX | Doxorubicin. |
| DSP | Dexamethasone sodium phosphate. |
| EPR | Enhanced permeability and retention. |
| EZH2 | Enhancer of Zeste Homolog 2. |
| FcRn | Fc receptor. |
| FDA | Food and Drug Administration. |
| G-CSF | Granulocyte colony-stimulating factor. |
| Gd2O3 | Gadolinium oxide. |
| GOD | Glucose oxidase. |
| gp60 | Glycoprotein 60 kDa. |
| GSH | Glutathione. |
| HSA | Human serum albumin. |
| HBNDSs | HSA-based nanodrug delivery systems. |
| HC | HSA conjugated with Ce6. |
| HO | HSA conjugated with oxaliplatin. |
| HCHOA | A nanoplatform by crosslinking azobenzene group between HC and HO. |
| HPTX | HSA conjugated with PTX-SS-C10-COOH. |
| HSA-BFP | A multifunctional nanoparticle based on basified HSA (HSA-B) by incorporating an Aβ fluorescent probe (F) and a cell-penetrating peptide (Penetratin, Pen). |
| HSAP | HSA-Pt (IV). |
| IL-10 | Interleukin-10. |
| INH | Isoniazid. |
| IR780 | IR780 iodide. |
| LDL-C | Low-density lipoprotein cholesterol. |
| MBS-A | Metal binding sites-A. |
| MBS-B | Metal binding sites-B. |
| MCP-1 | Monocyte chemotactic protein-1. |
| MI | Maleimide. |
| MMP | Matrix metalloproteinase. |
| MnO2 | Manganese dioxide. |
| MRN | Milrinone. |
| MTX | Methotrexate. |
| NCs | Nanocarriers. |
| NIR | Near-infrared. |
| NP(s) | Nanoparticle(s). |
| NTS | N-terminal binding site. |
| PA | Palmitic acid. |
| PCSK9 | Proprotein convertase subtilisin/kexin type 9. |
| PD | Prednisolone. |
| PD-L1 | Programmed cell death-ligand 1. |
| pDNA | Plasmid DNA. |
| PDT | Photodynamic therapy. |
| PDX | Patient-derived xenograft. |
| PEI | Polyethylenimine. |
| PEP | Albumin-binding peptide. |
| PFN | Photothermal Fenton nanocatalyst. |
| pHis | Polyhistidine. |
| PIC | Piceatannol. |
| PTT | Photothermal therapy. |
| Pt (IV)SA | Succinic acid-derivatized cisplatin prodrug. |
| PTX | Paclitaxel. |
| pVax | Peptide vaccine. |
| RA | Rheumatoid arthritis. |
| RB | Rose bengal. |
| RANTES | Regulated on activation, normal T cell expressed and secreted. |
| RGD | Arg-Gly-Asp. |
| RIF | Rifampicin. |
| ROS | Reactive oxygen species. |
| SCI | Spinal cord injury. |
| siRNA | Small interfering RNA. |
| SOD | Superoxide dismutase. |
| SPARC | Secreted protein acidic and rich in cysteine. |
| SPDP | N-succinimidyl-3-(2-pyridyldithio) propionate. |
| TAT | Trans-activator of transcription. |
| TME | Tumor microenvironment. |
| TMP | Tetramethylpyrazine. |
| 5-FU | 5-Fluorouracil. |